(secondQuint)Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612.

 Subjects were previously vaccinated at 11 to 17 months of age with GSK Biologicals' meningococcal vaccine 134612 or with Mencevax cent .

 This extension phase starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension phase.

 No new studies will be enrolled.

 The subjects will have 4 blood samples taken: at 24, 36, 48 and 60 months after vaccination.

.

 Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612@highlight

Subjects were previously vaccinated at 11 to 17 years of age.

 This extension phase starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension phase.

 No new subjects will be enrolled.

